bioAffinity Technologies, Inc. (BIAF) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.32
↓-87% vs avg
5yr avg: 2.51
30Y Low0.7·High4.2
ROE
↓
-242.4%
↑-75% vs avg
5yr avg: -138.7%
30Y Low-242%·High-74%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BIAF Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
bioAffinity Technologies, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $820796 | $11M | $13M | $7M | — | — | — |
| Enterprise Value | $1M | $11M | $12M | $-3963597 | — | — | — |
| P/E Ratio → | -0.09 | — | — | — | — | — | — |
| P/S Ratio | 0.09 | 1.18 | 5.08 | 1498.73 | — | — | — |
| P/B Ratio | 0.32 | 4.24 | 2.65 | 0.65 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BIAF EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.22 | 4.59 | -825.23 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
BIAF Profitability
Margins and return-on-capital ratios measuring operating efficiency
bioAffinity Technologies, Inc. earns an operating margin of -95.6%. Operating margins have expanded from -83511.5% to -95.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -242.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 36.1% | 36.1% | 31.3% | 90.3% | — | — | — |
| Operating Margin | -95.6% | -95.6% | -314.9% | -83511.5% | — | — | — |
| Net Profit Margin | -96.6% | -96.6% | -313.5% | -169771.2% | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -242.4% | -242.4% | -99.8% | -73.8% | — | — | — |
| ROA | -122.7% | -122.7% | -77.8% | -119.6% | -791.3% | -1807.2% | -502.0% |
| ROIC | -203.2% | -203.2% | -342.3% | — | — | — | — |
| ROCE | -190.8% | -190.8% | -93.7% | -36.3% | — | — | — |
BIAF Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $395903 ($2M total debt minus $1M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.58 | 0.58 | 0.33 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.15 | -0.26 | -1.01 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -96.82 | -96.82 | -214.76 | -1.58 | -2.20 | -6.81 | -14.39 |
BIAF Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.87x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 10.50x to 0.87x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.87 | 0.87 | 1.77 | 10.50 | 0.11 | 0.01 | 0.13 |
| Quick Ratio | 0.86 | 0.86 | 1.76 | 10.50 | 0.11 | 0.01 | 0.13 |
| Cash Ratio | 0.36 | 0.36 | 1.26 | 10.02 | 0.10 | 0.01 | 0.12 |
| Asset Turnover | — | 1.44 | 0.31 | 0.00 | — | — | — |
| Inventory Turnover | 216.71 | 216.71 | 94.19 | 0.08 | — | 0.78 | — |
| Days Sales Outstanding | — | 44.41 | 117.01 | 797.10 | — | — | — |
BIAF Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
bioAffinity Technologies, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $404333 | $291600 | $149967 | $245933 | $245933 | $245933 |
Peer Comparison
Compare BIAF with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BIAFYou | $820796 | -0.1 | — | — | 36.1% | -95.6% | -242.4% | -203.2% | — |
 LUNG | $53M | -0.9 | — | — | 74.2% | -59.3% | -77.2% | -72.0% | — |
 NVCR | $2B | -14.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 CDNA | $1B | -54.5 | — | 31.2 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 GKOS | $8B | -40.7 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 ILMN | $22B | 26.0 | 20.0 | 23.1 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $173B | 26.2 | 18.7 | 27.5 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $121B | 34.0 | 17.8 | 23.0 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 BIO | $7B | 9.1 | 16.5 | 18.3 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See BIAF's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIAF Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIAF vs LUNG
Side-by-side business, growth, and profitability comparison vs Pulmonx Corporation.
Start ComparisonBIAF — Frequently Asked Questions
Quick answers to the most common questions about buying BIAF stock.
What is bioAffinity Technologies, Inc.'s P/E ratio?
bioAffinity Technologies, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is bioAffinity Technologies, Inc.'s ROE?
bioAffinity Technologies, Inc.'s return on equity (ROE) is -242.4%. The historical average is -138.7%.
Is BIAF stock overvalued?
Based on historical data, bioAffinity Technologies, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are bioAffinity Technologies, Inc.'s profit margins?
bioAffinity Technologies, Inc. has 36.1% gross margin and -95.6% operating margin.